Recent Advances in Cancer Vaccines - An Update
DOI:
https://doi.org/10.6000/1929-2279.2012.01.02.3Keywords:
Immunotherapy, peptide vaccine, DNA vaccine, gardasil, cervarix, Sipleucel.Abstract
Cancer related deaths have shown a progressive increase over the past decade and the newer cases of cancers are estimated to rise in 2030. The current treatment modalities available for cancer are highly toxic, impair quality of life and develop resistance with course of time. Thus, there is a growing necessity for the prevention and cure of cancer related morbidity and mortality. One of the promising approaches for cancer prevention could be immunization with specific vaccines. The latest advances in immunology have led to the development of effective cancer vaccines to enhance immunity against tumour cells. Moreover, the occurrence of cancer with infectious agents like Hepatitis B virus (HBV) and Human Papilloma virus (HPV) as well as their prevention with specific cancer vaccines has further confirmed the role of immunotherapy in cancer. Though prophylactic vaccines are found to be more successful in cancer prevention, in the present scenario most of the vaccines under development are therapeutic cancer vaccines. Cancer vaccines stimulate the immune system and attack specific cancer cells without harming the normal cells. The major cancer vaccines under development to target tumour cells includes antigen vaccines, whole cell tumour vaccines, dendritic cell vaccine, viral vectors, DNA vaccines and idiotype vaccines. Apart from this, measures to produce patient-specific cancer vaccines from patients own tumour cells and a "universal" vaccine to provide immunity against cancer cells of any origin are being investigated. Hence this review gives an overview of various strategies involved in the development of cancer vaccines and the currently approved vaccines available for the prevention of cancer.
References
de Oliveira FA, Teixeira Vde P, Lino Rde S Jr., Guimarães JV, dos Reis MA. Causes of death in older people autopsied. Ann Diagn Pathol 2009; 13: 233-8. http://dx.doi.org/10.1016/j.anndiagpath.2009.04.002
World Health Organisation [homepage on the Internet]. c2008 [updated 2008 Apr 01; cited 2012 Sep 09]: Available from: http://www.who.int/features/qa/15/en/index.html
Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2009; 4: CD002093.
Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 2009; 18: 81-100.
McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006; 26: 154-8.
Wang E, Monaco A, Monsurró V, et al. Antitumor vaccines, immunotherapy and the immunological constant of rejection. I Drugs 2009; 12: 297-301.
Khazaie K, Bonertz A, Beckhove P. Current developments with peptide-based human tumor vaccines. Curr Opin Oncol 2009; 21: 524-30. http://dx.doi.org/10.1097/CCO.0b013e328331a78e
Palena C, Abrams SI, Schlom J, Hodge JW. Cancer vaccines: preclinical studies and novel strategies. Adv Cancer Res 2006; 95: 115-145. http://dx.doi.org/10.1016/S0065-230X(06)95004-0
Tovar JM, Bazaldua OV, Vargas L, Reile E. Human papillomavirus, cervical cancer, and the vaccines. Postgrad Med 2008; 120: 79-84. http://dx.doi.org/10.3810/pgm.2008.07.1794
FDA U.S Food and Drug Administration [homepage on the Internet]. c2011 [updated 2011 Oct 21; cited 2012 Sep 9]: Available from: http://www.fda.gov/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ucm094042.htm
Lewis JJ, Houghton AN. Definition of tumor antigens suitable for vaccine construction. Semin Cancer Biol 1995; 6: 321-7. http://dx.doi.org/10.1016/1044-579X(95)90001-2
Heimburg-Molinaro J, Almogren A, Morey S, et al. Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen. Neoplasia 2009; 11: 780-92.
Morris LF, Ribas A. Therapeutic cancer vaccines. Surg Oncol Clin N Am 2007; 16: 819-31. http://dx.doi.org/10.1016/j.soc.2007.07.007
Berzofsky JA, Terabe M. The contrasting roles of NKT cells in tumor immunity. Curr Mol Med 2009; 9: 667-72. http://dx.doi.org/10.2174/156652409788970706
Lotem M, Machlenkin A, Hamburger T, et al. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells. Clin Cancer Res 2009; 15: 4968-77. http://dx.doi.org/10.1158/1078-0432.CCR-08-3320
Shumway NM, Ibrahim N, Ponniah S, Peoples GE, Murray JL. Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs 2009; 23: 277-87. http://dx.doi.org/10.2165/11313490-000000000-00000
Borges VF, Kufe D, Avigan DE. Update on cancer vaccines. Curr Opin Gastroenterol 2002; 18: 723-31. http://dx.doi.org/10.1097/00001574-200211000-00015
Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy. Cytotherapy 2002; 4: 317-27. http://dx.doi.org/10.1080/146532402760271091
Riley CL, Mathieu MG, Clark RE, McArdle SE, Rees RC. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? Cancer Immunol Immunother 2009; 58: 1489-99. http://dx.doi.org/10.1007/s00262-009-0675-x
Kawakami Y. Identification of human tumor antigens recognized by T-cells and their use for immunotherapy. Int J Hematol 2003; 77: 427-34. http://dx.doi.org/10.1007/BF02986609
Brichard VG, Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin Biol Ther 2008; 8: 951-68. http://dx.doi.org/10.1517/14712598.8.7.951
Borrello IM, Sotomayor EM. Cancer vaccines for hematologic malignancies. Cancer Control 2002; 9: 138-51.
Kawakami Y, Fujita T, Matsuzaki Y, et al. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 2004; 95: 784-91. http://dx.doi.org/10.1111/j.1349-7006.2004.tb02182.x
Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapy. Semin Immunol 2008; 20: 276-85. http://dx.doi.org/10.1016/j.smim.2008.07.001
Henderson RA, Finn OJ. Human tumor antigens are ready to fly. Adv Immunol 1996; 62: 217-56. http://dx.doi.org/10.1016/S0065-2776(08)60431-9
Disis ML, Cheever MA. Oncogenic proteins as tumor antigens. Curr Opin Immunol 1996; 8: 637-42. http://dx.doi.org/10.1016/S0952-7915(96)80079-3
Carmichael MG, Benavides LC, Holmes JP, et al. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: united States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 2010; 116: 292-301. http://dx.doi.org/10.1002/cncr.24756
Mesa C, Fernandez LE. Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol 2004; 82: 644-50. http://dx.doi.org/10.1111/j.0818-9641.2004.01279.x
Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009; 18: 1217-25. http://dx.doi.org/10.1177/0961203309345724
Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183: 6186-97. http://dx.doi.org/10.4049/jimmunol.0901474
Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82: 488-96. http://dx.doi.org/10.1111/j.0818-9641.2004.01272.x
Mocellin S. Priming anticancer active specific immunotherapy with dendritic cells. Curr Opin Investig Drugs 2005; 6: 576-81.
Quah B, Ni K, O'Neill HC. In vitro hematopoiesis produces a distinct class of immature dendritic cells from spleen progenitors with limited T cell stimulation capacity. Int Immunol 2004; 16: 567-77. http://dx.doi.org/10.1093/intimm/dxh060
Palucka K, Ueno H, Fay J, Banchereau J. Harnessing dendritic cells to generate cancer vaccines. Ann N Y Acad Sci 2009; 117: 488-98.
Gustafson MP, Knutson KL, Dietz AB. Therapeutic vaccines for malignant brain tumors. Biologics 2008; 2: 753-61.
Matera L. The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev 2010; 36: 131-41. http://dx.doi.org/10.1016/j.ctrv.2009.11.002
Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 1998; 95: 10067-71. http://dx.doi.org/10.1073/pnas.95.17.10067
Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ. Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 2008; 57: 1559-68. http://dx.doi.org/10.1007/s00262-008-0553-y
Kaneno R, Shurin GV, Tourkova IL, Shurin MR. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med 2009; 7: 58. http://dx.doi.org/10.1186/1479-5876-7-58
Dunussi-Joannopoulos K. Malignancy: Gene Therapy Vaccines in Acute Myeloid Leukemia: A Need for Clinical Evaluation. Hematology 2000; 5: 103-15.
Sharma S, Miller P.W, Stolina M, et al. Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther 1997; 4: 1361-70. http://dx.doi.org/10.1038/sj.gt.3300531
Webster RG, Robinson HL. DNA vaccines: a review of developments. BioDrugs 1997; 8: 273-92. http://dx.doi.org/10.2165/00063030-199708040-00004
Ebben JD, Rocque BG, Kuo JS. Tumour vaccine approaches for CNS malignancies: progress to date. Drugs 2009; 69: 241-9. http://dx.doi.org/10.2165/00003495-200969030-00001
Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7. http://dx.doi.org/10.1038/nm0398-321
Rothbard JB. Synthetic peptides as vaccines. Biotechnology 1992; 20: 451-65.
Ahlers JD, Belyakov IM, Terabe M, et al. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc Natl Acad Sci USA 2002; 99: 13020-5. http://dx.doi.org/10.1073/pnas.192251199
Jabbari E. Targeted delivery with peptidomimetic conjugated self-assembled nanoparticles. Pharm Res 2009; 26: 612-30. http://dx.doi.org/10.1007/s11095-008-9802-1
Slingluff CL Jr., Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007; 13: 6386-95. http://dx.doi.org/10.1158/1078-0432.CCR-07-0486
Blumberg BS. Primary and secondary prevention of liver cancer caused by HBV. Front Biosci (Schol Ed) 2010; 2: 756-63. http://dx.doi.org/10.2741/s98
El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35: S72-8. http://dx.doi.org/10.1097/00004836-200211002-00002
Chang MH. Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res 2009; 181: 85-94. http://dx.doi.org/10.1007/978-3-540-69297-3_10
Bolhassani A, Mohit E, Rafati S. Different spectra of therapeutic vaccine development against HPV infections. Hum Vaccin 2009; 5: 671-89. http://dx.doi.org/10.4161/hv.5.10.9370
Garland SM. Can cervical cancer be eradicated by prophylactic HPV vaccination? Challenges to vaccine implementation. Indian J Med Res 2009; 130: 311-21.
Mahoney MC. Protecting our patients from HPV and HPV-related diseases: the role of vaccines. J Fam Pract 2006; Suppl 10-7.
Vesikari T, Van Damme P, Lindblad N, et al. An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine Given Concomitantly With Diphtheria, Tetanus, Pertussis, and Poliomyelitis Vaccine in Healthy Adolescents 11 to 17 Years of Age. Pediatr Infect Dis J 2010; 24: 314-8.
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-24.
Madrid-Marina V, Torres-Poveda K, López-Toledo G, García-Carrancá A. Advantages and disadvantages of current prophylactic vaccines against HPV. Arch Med Res 2009; 40: 471-7. http://dx.doi.org/10.1016/j.arcmed.2009.08.005
Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110: 525-41. http://dx.doi.org/10.1042/CS20050369
FDA U.S Food and Drug Administration [homepage on the Internet]: c2012 [updated 2012 Apr 24; cited 2012 Sep 9]: Available from: http://www.fda.gov/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ucm186959.htm
Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009; 8: 1663-79. http://dx.doi.org/10.1586/erv.09.123
Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. Clin Infect Dis 2007; 45: 609-7. http://dx.doi.org/10.1086/520654
Doehn C, Böhmer T, Kausch I, Sommerauer M, Jocham D. Prostate cancer vaccines: current status and future potential. BioDrugs 2008; 22: 71-84. http://dx.doi.org/10.2165/00063030-200822020-00001
Harzstark AL, Small EJ. Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc) 2008; 44: 271-8. http://dx.doi.org/10.1358/dot.2008.44.4.1212301
Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-94. http://dx.doi.org/10.1200/JCO.2005.04.5252
Doehn C, Böhmer T, Kausch I, Sommerauer M, Jocham D. Prostate cancer vaccines: current status and future potential. BioDrugs 2008; 22: 71-84. http://dx.doi.org/10.2165/00063030-200822020-00001
Andersen MH, Sørensen RB, Schrama D, Svane IM, Becker JC, Thor Straten P. Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother 2008; 57: 1735-43. http://dx.doi.org/10.1007/s00262-008-0480-y
Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 2008; 4: 16-25. http://dx.doi.org/10.1634/theoncologist.13-S4-16
Schlom J, Arlen PM, Gulley L. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007; 13: 3776-82. http://dx.doi.org/10.1158/1078-0432.CCR-07-0588
Brooks NA, Pouniotis DS, Tang CK, Apostolopoulos V, Pietersz GA. Cell-penetrating peptides: Application in vaccine delivery. Biochim Biophys Acta 2010; 1805: 25-34.
Monie A, Tsen SW, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Expert Rev Vaccines 2009; 8: 1221-35. http://dx.doi.org/10.1586/erv.09.7
Downloads
Published
How to Cite
Issue
Section
